Patients with refractory or relapsed Philadelphia chromosome-positive acute lymphoblastic
leukemia (Ph+ ALL) rarely have prolonged responses to salvage therapy, including imatinib …

Hematologic relapse remains the greatest obstacle to the cure of children with acute
lymphoblastic leukemia (ALL). Recent studies have shown that patients with increased risk …

BACKGROUND AND OBJECTIVES: The limited value of qualitative reverse transcription
polymerase chain-reaction (RT-PCR) for monitoring chronic myeloid leukemia (CML) …

Abstract Background: BCR-ABL fusion mRNA expression in bone marrow or peripheral
blood can be used as a measure of minimal residual disease in patients with chronic …

Autologous transplantation of gene-modified hematopoietic stem cells may provide a
therapeutic strategy for several monogeneic disorders. In previous studies, retroviral gene …

Epigenetic disorders play a key role in tumorigenesis and development, among which
histone methylation abnormalities are common. While patients living with chronic myeloid …

Fragile sites are specific regions of chromosomes prone to breakage when cells are cultured
under specific conditions. These sites are divided into two classes: common and rare …

We compared the effect of control genes (CG): total Abelson (total-ABL), beta-2-
microglobulin (B2M) and beta-glucuronidase (GUS), recommended in the Europe Against …

Although tyrosine kinase inhibitors (TKIs) have revolutionized the treatment of chronic
myeloid leukaemia (CML), TKI resistance remains a major challenge. Here, we …

We developed and extensively validated a real-time PCR assay for the quantitation of bcr-
abl to determine residual disease in patients with chronic myelogenous leukemia. This …